DD263232A5 - Therapeutische mittel - Google Patents
Therapeutische mittel Download PDFInfo
- Publication number
- DD263232A5 DD263232A5 DD87300859A DD30085987A DD263232A5 DD 263232 A5 DD263232 A5 DD 263232A5 DD 87300859 A DD87300859 A DD 87300859A DD 30085987 A DD30085987 A DD 30085987A DD 263232 A5 DD263232 A5 DD 263232A5
- Authority
- DD
- German Democratic Republic
- Prior art keywords
- ibuprofen
- aggregate material
- granules
- crystalline ibuprofen
- crystalline
- Prior art date
Links
- 239000003814 drug Substances 0.000 title description 2
- 229940124597 therapeutic agent Drugs 0.000 title description 2
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 claims abstract description 129
- 229960001680 ibuprofen Drugs 0.000 claims abstract description 128
- 239000000463 material Substances 0.000 claims abstract description 63
- 239000000203 mixture Substances 0.000 claims abstract description 62
- 238000000034 method Methods 0.000 claims abstract description 34
- 239000002245 particle Substances 0.000 claims abstract description 23
- 239000007787 solid Substances 0.000 claims abstract description 23
- 239000013078 crystal Substances 0.000 claims abstract description 17
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 13
- 238000004220 aggregation Methods 0.000 claims abstract description 5
- 230000002776 aggregation Effects 0.000 claims abstract description 5
- 238000007906 compression Methods 0.000 claims abstract description 5
- 230000006835 compression Effects 0.000 claims abstract description 5
- 239000008187 granular material Substances 0.000 claims description 89
- 239000007788 liquid Substances 0.000 claims description 21
- 238000001125 extrusion Methods 0.000 claims description 10
- 238000001035 drying Methods 0.000 claims description 8
- 238000004898 kneading Methods 0.000 claims description 7
- 238000002156 mixing Methods 0.000 claims description 5
- 238000007873 sieving Methods 0.000 claims description 5
- 239000003937 drug carrier Substances 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 239000007909 solid dosage form Substances 0.000 claims description 4
- 238000005520 cutting process Methods 0.000 claims description 3
- 238000005469 granulation Methods 0.000 claims description 3
- 230000003179 granulation Effects 0.000 claims description 3
- 239000004215 Carbon black (E152) Substances 0.000 claims description 2
- 230000009471 action Effects 0.000 claims description 2
- 229930195733 hydrocarbon Natural products 0.000 claims description 2
- 150000002430 hydrocarbons Chemical class 0.000 claims description 2
- 238000003825 pressing Methods 0.000 claims description 2
- 238000009472 formulation Methods 0.000 abstract description 22
- 238000002360 preparation method Methods 0.000 abstract description 15
- 230000008569 process Effects 0.000 abstract description 14
- 239000000546 pharmaceutical excipient Substances 0.000 description 11
- 238000000354 decomposition reaction Methods 0.000 description 10
- 238000004090 dissolution Methods 0.000 description 10
- 229920002785 Croscarmellose sodium Polymers 0.000 description 9
- 238000004525 petroleum distillation Methods 0.000 description 9
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 8
- 229960001681 croscarmellose sodium Drugs 0.000 description 8
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 8
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 7
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 7
- 229940016286 microcrystalline cellulose Drugs 0.000 description 7
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 7
- 239000008108 microcrystalline cellulose Substances 0.000 description 7
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 7
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
- 235000021355 Stearic acid Nutrition 0.000 description 6
- 239000004615 ingredient Substances 0.000 description 6
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 6
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 6
- 239000008117 stearic acid Substances 0.000 description 6
- 238000003860 storage Methods 0.000 description 6
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 5
- 239000008101 lactose Substances 0.000 description 5
- 239000011521 glass Substances 0.000 description 4
- 235000019359 magnesium stearate Nutrition 0.000 description 4
- 239000000454 talc Substances 0.000 description 4
- 229910052623 talc Inorganic materials 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- 239000011324 bead Substances 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 239000007853 buffer solution Substances 0.000 description 3
- 239000001506 calcium phosphate Substances 0.000 description 3
- 239000011248 coating agent Substances 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 239000008119 colloidal silica Substances 0.000 description 3
- 230000009969 flowable effect Effects 0.000 description 3
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 3
- 229910052753 mercury Inorganic materials 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- CBQYNPHHHJTCJS-UHFFFAOYSA-N Alline Chemical compound C1=CC=C2C3(O)CCN(C)C3NC2=C1 CBQYNPHHHJTCJS-UHFFFAOYSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 230000000202 analgesic effect Effects 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 239000012298 atmosphere Substances 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000005056 compaction Methods 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000000227 grinding Methods 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 238000002459 porosimetry Methods 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 238000013268 sustained release Methods 0.000 description 2
- 239000012730 sustained-release form Substances 0.000 description 2
- 229940078499 tricalcium phosphate Drugs 0.000 description 2
- 229910000391 tricalcium phosphate Inorganic materials 0.000 description 2
- 235000019731 tricalcium phosphate Nutrition 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- NTIZESTWPVYFNL-UHFFFAOYSA-N Methyl isobutyl ketone Chemical compound CC(C)CC(C)=O NTIZESTWPVYFNL-UHFFFAOYSA-N 0.000 description 1
- UIHCLUNTQKBZGK-UHFFFAOYSA-N Methyl isobutyl ketone Natural products CCC(C)C(C)=O UIHCLUNTQKBZGK-UHFFFAOYSA-N 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 235000010724 Wisteria floribunda Nutrition 0.000 description 1
- VJHCJDRQFCCTHL-UHFFFAOYSA-N acetic acid 2,3,4,5,6-pentahydroxyhexanal Chemical compound CC(O)=O.OCC(O)C(O)C(O)C(O)C=O VJHCJDRQFCCTHL-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 235000011132 calcium sulphate Nutrition 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 239000007931 coated granule Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229960005168 croscarmellose Drugs 0.000 description 1
- 239000001767 crosslinked sodium carboxy methyl cellulose Substances 0.000 description 1
- 239000002178 crystalline material Substances 0.000 description 1
- 238000000280 densification Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 238000011038 discontinuous diafiltration by volume reduction Methods 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000007792 gaseous phase Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 125000002887 hydroxy group Chemical class [H]O* 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 229920001206 natural gum Polymers 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229940068977 polysorbate 20 Drugs 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 238000005204 segregation Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 235000002639 sodium chloride Nutrition 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 229940080313 sodium starch Drugs 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 238000009495 sugar coating Methods 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- -1 troche Substances 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 238000005550 wet granulation Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Pain & Pain Management (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Steroid Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Polyurethanes Or Polyureas (AREA)
- Medical Preparation Storing Or Oral Administration Devices (AREA)
- Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB868606762A GB8606762D0 (en) | 1986-03-19 | 1986-03-19 | Therapeutic agents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DD263232A5 true DD263232A5 (de) | 1988-12-28 |
Family
ID=10594868
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DD87300859A DD263232A5 (de) | 1986-03-19 | 1987-03-17 | Therapeutische mittel |
Country Status (21)
| Country | Link |
|---|---|
| EP (1) | EP0241126B1 (is") |
| JP (1) | JPS62230723A (is") |
| KR (1) | KR870008582A (is") |
| CN (1) | CN87101974A (is") |
| AT (1) | ATE65393T1 (is") |
| AU (1) | AU7017787A (is") |
| CS (1) | CS182787A2 (is") |
| DD (1) | DD263232A5 (is") |
| DE (1) | DE3771544D1 (is") |
| DK (1) | DK136487A (is") |
| FI (1) | FI871112L (is") |
| GB (2) | GB8606762D0 (is") |
| HU (1) | HU195422B (is") |
| IL (1) | IL81884A0 (is") |
| IN (1) | IN163939B (is") |
| NO (1) | NO871120L (is") |
| NZ (1) | NZ219560A (is") |
| PL (1) | PL264695A1 (is") |
| PT (1) | PT84526B (is") |
| YU (1) | YU47087A (is") |
| ZA (1) | ZA871836B (is") |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3833448A1 (de) * | 1988-10-01 | 1990-04-12 | Hoechst Ag | Verfahren zur gewinnung von ibuprofen fuer die direkttablettierung |
| NZ234587A (en) * | 1989-08-04 | 1991-11-26 | Mcneil Ppc Inc | A chewable pharmaceutical tablet of compressed coated granules |
| CA2063141C (en) * | 1989-08-04 | 1997-03-04 | Edward J. Roche | Rotogranulations and taste masking coatings for preparation of chewable pharmaceutical tablets |
| US5191114A (en) * | 1991-10-09 | 1993-03-02 | Sage Pharmaceuticals, Inc. | Process for enhancing the flow characteristics of ibuprofen |
| US5605930A (en) * | 1991-10-21 | 1997-02-25 | The United States Of America As Represented By The Department Of Health And Human Services | Compositions and methods for treating and preventing pathologies including cancer |
| AU1193092A (en) * | 1992-01-10 | 1993-08-03 | Obschestvo S Ogranichennoi Otvetstvennostju Meditsinsky Nauchno-Proizvodstvenny Komplex Biotiki | Granulated pharmaceutical composition and method of obtaining it |
| PT721331E (pt) * | 1993-10-01 | 2002-05-31 | Astrazeneca Ab | Processo i |
| IS1736B (is) * | 1993-10-01 | 1999-12-30 | Astra Ab | Aðferð og tæki sem stuðla að aukinni samloðun agna |
| TWI225402B (en) | 1996-03-13 | 2004-12-21 | Biochemie Gmbh | Auxiliary-free agglomerates |
| FR2804603B1 (fr) * | 2000-02-04 | 2004-01-23 | Rhodia Chimie Sa | Procede continu pour formuler sous forme de granules une ou plusieurs matieres actives pharmaceutiques |
| DE102005037630A1 (de) | 2005-08-09 | 2007-02-15 | Glatt Gmbh | Verfahren zur Herstellung von Teilchen aus pharmazeutischen Substanzen, Teilchen aus pharmazeutischen Substanzen sowie deren Verwendung |
| WO2014078435A1 (en) | 2012-11-14 | 2014-05-22 | W. R. Grace & Co.-Conn. | Compositions containing a biologically active material and a non-ordered inorganic oxide |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4476248A (en) * | 1983-02-28 | 1984-10-09 | The Upjohn Company | Crystallization of ibuprofen |
| JPS60120616A (ja) * | 1983-12-05 | 1985-06-28 | Yaskawa Electric Mfg Co Ltd | プリセット型可逆カウンタ装置 |
| US4609675A (en) * | 1984-08-17 | 1986-09-02 | The Upjohn Company | Stable, high dose, high bulk density ibuprofen granulations for tablet and capsule manufacturing |
-
1986
- 1986-03-19 GB GB868606762A patent/GB8606762D0/en active Pending
-
1987
- 1987-03-03 EP EP87301825A patent/EP0241126B1/en not_active Expired - Lifetime
- 1987-03-03 GB GB8704987A patent/GB2187952B/en not_active Revoked
- 1987-03-03 AT AT87301825T patent/ATE65393T1/de active
- 1987-03-03 DE DE8787301825T patent/DE3771544D1/de not_active Expired - Fee Related
- 1987-03-10 NZ NZ219560A patent/NZ219560A/xx unknown
- 1987-03-12 IN IN174/MAS/87A patent/IN163939B/en unknown
- 1987-03-13 FI FI871112A patent/FI871112L/fi not_active IP Right Cessation
- 1987-03-13 ZA ZA871836A patent/ZA871836B/xx unknown
- 1987-03-13 IL IL81884A patent/IL81884A0/xx unknown
- 1987-03-17 DK DK136487A patent/DK136487A/da not_active Application Discontinuation
- 1987-03-17 DD DD87300859A patent/DD263232A5/de not_active IP Right Cessation
- 1987-03-18 JP JP62063658A patent/JPS62230723A/ja active Pending
- 1987-03-18 HU HU871184A patent/HU195422B/hu not_active IP Right Cessation
- 1987-03-18 KR KR870002431A patent/KR870008582A/ko not_active Withdrawn
- 1987-03-18 CS CS871827A patent/CS182787A2/cs unknown
- 1987-03-18 PL PL1987264695A patent/PL264695A1/xx unknown
- 1987-03-18 NO NO871120A patent/NO871120L/no unknown
- 1987-03-19 PT PT84526A patent/PT84526B/pt not_active IP Right Cessation
- 1987-03-19 CN CN198787101974A patent/CN87101974A/zh active Pending
- 1987-03-19 YU YU00470/87A patent/YU47087A/xx unknown
- 1987-03-19 AU AU70177/87A patent/AU7017787A/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| HUT42939A (en) | 1987-09-28 |
| HU195422B (en) | 1988-05-30 |
| IL81884A0 (en) | 1987-10-20 |
| KR870008582A (ko) | 1987-10-19 |
| GB2187952B (en) | 1990-05-09 |
| EP0241126A1 (en) | 1987-10-14 |
| CN87101974A (zh) | 1987-10-21 |
| FI871112A0 (fi) | 1987-03-13 |
| FI871112A7 (fi) | 1987-09-20 |
| GB2187952A (en) | 1987-09-23 |
| DE3771544D1 (de) | 1991-08-29 |
| FI871112L (fi) | 1987-09-20 |
| GB8606762D0 (en) | 1986-04-23 |
| PT84526A (en) | 1987-04-01 |
| DK136487A (da) | 1987-09-20 |
| GB8704987D0 (en) | 1987-04-08 |
| IN163939B (is") | 1988-12-10 |
| NO871120L (no) | 1987-09-21 |
| DK136487D0 (da) | 1987-03-17 |
| PL264695A1 (en) | 1988-05-12 |
| JPS62230723A (ja) | 1987-10-09 |
| ZA871836B (en) | 1987-09-02 |
| NO871120D0 (no) | 1987-03-18 |
| PT84526B (pt) | 1989-11-10 |
| NZ219560A (en) | 1989-05-29 |
| YU47087A (en) | 1988-04-30 |
| AU7017787A (en) | 1987-09-24 |
| EP0241126B1 (en) | 1991-07-24 |
| CS182787A2 (en) | 1991-05-14 |
| ATE65393T1 (de) | 1991-08-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69400215T2 (de) | Tramadol enthaltendes Arzneimittel mit verzögerter Wirkstoffabgabe | |
| DE69412295T2 (de) | Verfahren zur Herstellung von Mikrogranulaten, die nach Umhüllung zur Suspendierung in flüssigen Pharmazeutika geeignet sind | |
| DE3877764T2 (de) | Ein freifliessendes granulat, enthaltend ibuprofen und ein herstellunsgverfahren. | |
| DE69434640T2 (de) | Heterodisperse Hydrogelsysteme zur verzögerten Freisetzung unlöslicher Arzneistoffe | |
| DE69231499T2 (de) | Zusammensetzung auf der basis von mikrokristalliner zellulose für die herstellung von kugelförmigen teilchen | |
| EP3174530B1 (de) | Direkt verpressbare polyvinylalkohole | |
| DE2412117A1 (de) | Verfahren zur herstellung von granulaten | |
| DE3503681A1 (de) | Pharmazeutische zusammensetzungen | |
| DE2816055A1 (de) | Neuer excipient und diesen enthaltende pharmazeutische zusammensetzung | |
| DE2721603C3 (de) | Beschichtete Körnchen aus Alkalimetallsalzen der Polyacrylsäure und Verfahren zu ihrer Herstellung | |
| WO2003028698A2 (de) | Verfahren und vorrichtung zur herstellung von granulaten umfassend mindestens einen pharmazeutischen wirkstoff | |
| DE2736794A1 (de) | Pharmazeutische dosierungsformen mit anhaltender wirkung | |
| DE2307747A1 (de) | Propoxyphennapsylat-praeparat mit zeitgesteuerter wirkstofffreisetzung und verfahren zu seiner herstellung | |
| DE1278699B (de) | Verfahren zur Herstellung von Tabletten | |
| DD263232A5 (de) | Therapeutische mittel | |
| DE69624364T2 (de) | Abführmittel enthaltend lactitol und psyllium | |
| DE60306120T2 (de) | Pharmazeutische formulierung, die n-((1-n-butyl-4-piperidinyl)menthyl)-3,4-dihydro-2h-(1,3)oxazino(3,2-a)indol-10-carboxamid oder ein entsprechendes salz hiervon enthält, sowie deren herstellungsprozess, welcher trockengranulierung beinhaltet | |
| DE2241960C2 (de) | Freifließendes Granulat zur Tablettenherstellung | |
| DE2706660A1 (de) | Ascorbinsaeure enthaltende granulate und verfahren zu ihrer herstellung | |
| EP1443906A1 (de) | Verfahren zur bildung von profenkristallen | |
| DE3150557C2 (is") | ||
| EP3721870A1 (de) | Verfahren zur kontinuierlichen herstellung eines wirkstoffgranulats | |
| EP0164571B1 (de) | Retardformen des alpha-(2,5-Dimethoxy-phenyl)-beta-lycinamido-äthanols und Verfahren zu ihrer Herstellung | |
| DE3781368T2 (de) | Granulierte trikalziumphosphat-zusammensetzungen, geeignet zur tablettierung durch direkte kompression. | |
| DE2050701C3 (de) | Verwendung eines pulverförmigen Celluloseäthers als Hilfsstoff zur Herstellung von leicht zerfallbaren festen Arzneiformen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| ENJ | Ceased due to non-payment of renewal fee |